Increase in adoption of in-vitro models, rise in R&D activities in the healthcare sector, surge in drug development activities for novel diseases and technological advancements drive the demand for early toxicity testing across the world. The demand for toxicity testing during the pre-clinical trials has been increased to determine the safety and effectiveness of new drug candidates. Market players have adopted the collaboration strategy to carry out pre-clinical trials and utilizing expertise of each other to carry out testing successfully. The Asia-Pacific region is projected to witness a significant growth, due to adoption of various strategies by market players and and surge in R&D investments in the drug development processes.
Carrying
out early toxicity testing at pre-clinical stages in the process of drug
development is crucial as toxicity may be the prime reason for drug candidate
failure. If the toxicity is determined at the later stages of the drug
development process, there may be huge financial losses for developers. Well
designed and seamlessly executed pre-clinical trials are essential for drug
development programs. The demand for early toxicity testing is expected to
surge considerably in the coming years. According to the report published by
Allied Market Research, the global early toxicity
testing market is expected to reach $1.30 billion by 2025. Following are some of the
activities taking place across the world.
Increase in R&D activities in healthcare, surge in
stringency of regulatory authorities concerning public healthcare welfare, and
rise in adoption of in vitro model and early toxicity testing have boosted the
growth of the Europe early toxicity
testing market. However, the limitations of preclinical testing hamper the
market growth. On the contrary, technological advancements in the field of
early toxicity testing are expected to create lucrative opportunities in the
near future.
Market
players have been adopting the strategy of collaboration to conduct toxicity
testing. Affyxell Therapeutics collaborated with Korea Non-Clinical Technology
Solution Center (KNTSC) and Biocytogen. This strategy will help in conducting
efficient pre-clinical trials. In the drug development stage, pre-clinical
trials play a vital role in determining the safety of new drug candidates and
the relationship between particular genes and diseases. Through the
collaboration, Affyxell Therapeutics aims to carry out toxicity testing of some
of its drug candidates with the help of animal and disease models. The company
will determine the efficacy of new drug candidates for various diseases.
Among
various techniques adopted to carry out early toxicity testing, the in-vitro technique
is expected to continue its wide implementation in the next few years. This is
due to its cost-effective nature, stringent regulations on animal testing, and
advancements in technology. On the other hand, the adoption of the in-silico
technique is expected to increase as it provides computer-based testing models
that eliminate the need for testing on animals. This technique has a potential
to revolutionize the drug development process.
Factors that drive the
growth of the market include rise in R&D activities and surge in stringent
regulatory authorities concerning public healthcare welfare. Increase in
adoption of in vitro model which is the major current early toxicity testing
market trend also boosts the growth of the market. However, challenges of
preclinical testing hamper the market growth. Furthermore, technological
advancements in preclinical diagnostic equipment provide lucrative
opportunities for the early toxicity testing market growth.
The report includes in-depth analysis of the major market players such as General Electric Company (GE Healthcare), Agilent Technologies, Inc., Evotec AG (Cyprotex), Danaher Corporation (Beckman Coulter, Inc.), Bruker Corporation, Bioanalytical Systems, Inc., PerkinElmer Inc., Thermo Fisher Scientific, Inc., The Jackson Laboratory, and Enzo Biochem, Inc. (Enzo Clinical Labs, Inc.).
0 Comments